Get the Stockscreener App
99.21
0.31%
-0.31
After Hours:
103.80
4.59
+4.63%
Protagonist Therapeutics Inc stock is traded at $99.21, with a volume of 391.03K.
It is down -0.31% in the last 24 hours and down -4.40% over the past month.
Protagonist Therapeutics Inc is a biopharmaceutical company engaged in the discovery and development of peptide-based therapeutics using its proprietary technology platform. The company focuses on three therapeutic areas: inflammation and immunology, hematology, and metabolic diseases. Its pipeline includes clinical-stage and preclinical candidates such as rusfertide for polycythemia vera, icotrokinra for inflammatory diseases, and other programs targeting IL-17, obesity, and iron metabolism disorders, developed through internal research and strategic collaborations.
See More
Previous Close:
$99.52
Open:
$100.32
24h Volume:
391.03K
Relative Volume:
0.52
Market Cap:
$6.38B
Revenue:
$46.02M
Net Income/Loss:
$-130.15M
P/E Ratio:
-48.57
EPS:
-2.0427
Net Cash Flow:
$56.08M
1W Performance:
-1.98%
1M Performance:
-4.40%
6M Performance:
+27.39%
1Y Performance:
+124.05%
1-Day Range:
$97.45
$101.37
1-Week Range:
$97.08
$101.37
52-Week Range:
$41.28
$107.84
Protagonist Therapeutics Inc Stock (PTGX) Company Profile
Name
Protagonist Therapeutics Inc
Sector
Industry
Phone
(510) 474-0170
Address
7707 GATEWAY BLVD., SUITE 140, NEWARK, CA
Compare PTGX vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PTGX
Protagonist Therapeutics Inc
|
99.21 | 6.40B | 46.02M | -130.15M | 56.08M | -2.0427 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 109.34B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 74.35B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 50.44B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 39.78B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.02B | 5.36B | 287.73M | 924.18M | 2.5229 |
Protagonist Therapeutics Inc Stock (PTGX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-17-25 | Initiated | Barclays | Overweight |
| Sep-12-25 | Initiated | Leerink Partners | Outperform |
| Jun-17-25 | Initiated | Citigroup | Buy |
| Dec-06-24 | Initiated | BMO Capital Markets | Outperform |
| Dec-06-24 | Initiated | Goldman | Neutral |
| Nov-05-24 | Initiated | Wedbush | Outperform |
| Sep-24-24 | Initiated | TD Cowen | Buy |
| Sep-09-24 | Initiated | Truist | Buy |
| Oct-30-23 | Initiated | CapitalOne | Overweight |
| May-25-23 | Resumed | Jefferies | Buy |
| Aug-25-22 | Initiated | JMP Securities | Mkt Outperform |
| Feb-11-22 | Initiated | BTIG Research | Buy |
| Oct-12-21 | Upgrade | JP Morgan | Neutral → Overweight |
| Oct-11-21 | Upgrade | Northland Capital | Market Perform → Outperform |
| Sep-20-21 | Downgrade | JP Morgan | Overweight → Neutral |
| May-24-21 | Initiated | JMP Securities | Mkt Outperform |
| May-24-21 | Initiated | Northland Capital | Outperform |
| Jan-06-21 | Initiated | JP Morgan | Overweight |
| Dec-16-20 | Initiated | Piper Sandler | Overweight |
| Sep-18-20 | Reiterated | H.C. Wainwright | Buy |
| Jul-15-20 | Initiated | Jefferies | Buy |
| May-18-20 | Reiterated | H.C. Wainwright | Buy |
| Jul-08-19 | Initiated | H.C. Wainwright | Buy |
| May-09-19 | Upgrade | Stifel | Hold → Buy |
| Dec-06-18 | Initiated | Nomura | Buy |
| Jan-29-18 | Initiated | Stifel | Buy |
| Jul-21-17 | Initiated | BTIG Research | Buy |
View All
Protagonist Therapeutics Inc Stock (PTGX) Latest News
Protagonist Therapeutics (NASDAQ:PTGX) Posts Earnings Results, Beats Expectations By $0.70 EPS - MarketBeat
Milestones and Takeda opt-out reshape Protagonist (NASDAQ: PTGX) outlook - Stock Titan
Protagonist Reports First Quarter 2026 Financial Results and Provides Corporate Update - ACCESS Newswire
Protagonist (NASDAQ: PTGX) posts Q1 profit amid ICOTYDE approval and $200M rusfertide opt-out - Stock Titan
Protagonist Therapeutics set to report as blockbuster bets grow - Investing.com
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
(PTGX) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
MSN Money - MSN
Protagonist Therapeutics Inc. (PTGX): Billionaire Tom Steyer Likes Upside Potential of This Stock - Insider Monkey
331,164 Shares in Protagonist Therapeutics, Inc. $PTGX Bought by Jennison Associates LLC - MarketBeat
M&T Bank Corp Acquires New Holdings in Protagonist Therapeutics, Inc. $PTGX - MarketBeat
PTGX SEC FilingsProtagonist Ther 10-K, 10-Q, 8-K Forms - Stock Titan
Vanguard shows 5.09% stake in Protagonist Therapeutics (NASDAQ: PTGX) - Stock Titan
Pictet Asset Management Holding SA Has $46.26 Million Stock Position in Protagonist Therapeutics, Inc. $PTGX - MarketBeat
Vanguard reports 3.53M-share stake in Protagonist Therapeutics (NASDAQ: PTGX) - Stock Titan
Truist Financial Maintains Protagonist Therapeutics(PTGX.US) With Buy Rating - Moomoo
Blood cancer drug translates into $200 million payday for Bay Area company — and there's more to come - The Business Journals
Protagonist Therapeutics, Inc. $PTGX Shares Sold by Moody Aldrich Partners LLC - MarketBeat
UBS Group AG Acquires 874,013 Shares of Protagonist Therapeutics, Inc. $PTGX - MarketBeat
Protagonist Therapeutics (PTGX) Projected to Post Quarterly Earnings on Wednesday - MarketBeat
[ARS] Protagonist Therapeutics, Inc SEC Filing - Stock Titan
Protagonist Therapeutics (NASDAQ: PTGX) plans 2026 meeting and expanded equity plan - Stock Titan
Protagonist Therapeutics (PTGX) soars 4.7%: Is further upside left in the stock? - MSN
Takeda (TAK) and Protagonist Therapeutics Deal Revisited - GuruFocus
Protagonist Therapeutics Opts Out of Rusfertide US Profit-Sharing Arrangement With Takeda Pharmaceutical - marketscreener.com
Protagonist Exercises Rusfertide U.S. Opt-Out Right Under Takeda Collaboration - Voice of Alexandria
Takeda takes U.S. rights to rusfertide; Protagonist eligible for $475M - Stock Titan
PTGX Stock Price, Quote & Chart | PROTAGONIST THERAPEUTICS INC (NASDAQ:PTGX) - ChartMill
Protagonist Therapeutics Shifts Focus to High Margin Commercial Royalties - HarianBasis.co
Protagonist Therapeutics Inc. (PTGX): Billionaire Joe Edelman Likes This Stock - Yahoo Finance
Protagonist Therapeutics, Inc. $PTGX Shares Purchased by Universal Beteiligungs und Servicegesellschaft mbH - MarketBeat
CEO of Protagonist (NASDAQ: PTGX) makes bona fide share gift - Stock Titan
PTGX News | PROTAGONIST THERAPEUTICS INC (NASDAQ:PTGX) - ChartMill
PTGX (Protagonist Therapeutics Inc.) rises 2.17 percent even as Q4 2025 EPS falls far below analyst consensus estimates.Profit Guidance - UBND thành phố Hải Phòng
How (PTGX) Movements Inform Risk Allocation Models - Stock Traders Daily
Polycythemia Vera Market Set for Transformation: Key 9 Companies Expected to Enter by 2036 | DelveInsight - GlobeNewswire Inc.
Insider Selling: Protagonist Therapeutics (NASDAQ:PTGX) CFO Sells 1,750 Shares of Stock - MarketBeat
Protagonist Therapeutics CFO Ali Asif sells $184,572 in shares - Investing.com
Protagonist Therapeutics CFO Ali Asif sells $184,572 in shares By Investing.com - Investing.com Australia
Protagonist Therapeutics (NASDAQ: PTGX) CFO sells shares to cover RSU taxes - Stock Titan
PTGX (NASDAQ) Form 144: 1,750-share sale noted; insider disposals listed - Stock Titan
Protagonist Therapeutics stock rallies nearly 7% in a week: Here's why - MSN
Protagonist Therapeutics (PTGX) price target increased by 11.65% to 114.50 - MSN
Protagonist Therapeutics Reports Granting of Inducement Awards - ACCESS Newswire
Two new hires get rights to 69,850 Protagonist shares in awards - Stock Titan
PTGX Maintained by Truist Securities -- Price Target Raised to $121 - GuruFocus
Polycythemia Vera Market: Rapid Increment Driven by Innovation by 2034 – DelveInsight | Protagonist Therapeutics, Italfarmaco, Imago BioSciences, Silence Therapeutics, Ionis Pharma, Perseus Proteomics - Barchart.com
Polycythemia Vera Market: Rapid Increment Driven by Innovation - openPR.com
Truist Financial Maintains Protagonist Therapeutics(PTGX.US) With Buy Rating, Maintains Target Price $121 - Moomoo
Wedbush Maintains Protagonist Therapeutics(PTGX.US) With Buy Rating, Maintains Target Price $112 - Moomoo
Protagonist Therapeutics (PTGX) Stock Price Target Hike (Investor Interest) 2026-04-15Momentum Signals - UBND thành phố Hải Phòng
Protagonist Therapeutics Inc Stock (PTGX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.14%
0.48%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):